Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP - Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.50 and traded as low as $0.46. Elite Pharmaceuticals shares last traded at $0.47, with a volume of 463,596 shares trading hands.
Elite Pharmaceuticals Stock Performance
The firm has a fifty day moving average of $0.49 and a 200-day moving average of $0.50. The stock has a market capitalization of $470.08 million, a price-to-earnings ratio of -22.00 and a beta of 0.14. The company has a quick ratio of 1.90, a current ratio of 3.27 and a debt-to-equity ratio of 0.12.
Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. Elite Pharmaceuticals had a negative return on equity of 6.92% and a negative net margin of 25.70%.
Elite Pharmaceuticals Company Profile
(
Get Free Report)
Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
Recommended Stories
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
